$INDP

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On October 16, 2026, the Company completed the Private Placement, having received the full purchase price from each of the Purchasers in accordance with the terms of the Purchase Agreement, as amended. In connection with the closing of the Private Placeme

NewGen IVF (NIVF) rose 25% after a $1.25M share offering. SeaStar Medical (ICU) gained 23% on regulatory updates. Atara Biotherapeutics (ATRA) climbed 11% with a BLA resubmission. Indaptus Therapeutics (INDP) increased 9% without specific news. All stocks traded higher on Friday.

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed in the Current Report on Form 8-K filed by Indaptus Therapeutics, Inc. (the “ Company ”) with the Securities and Exchange Commission on September 9, 2026 (the “ Prior Form 8-K ”), on September 8, 2026,

PDS Biotech (PDSB) announced a $22.55M PIPE financing for late-stage cancer drug development, shares up 50.64%. Avaí Bio (AVAI) completed cell bank testing, shares up 14.29%. Clene (CLNN) priced a $4M offering, shares up 25.25%. NurExone (NRX.V) partnered with NanoPass, shares up 8.06%. Cardiff Oncology (CRDF) settled a licensing dispute, shares up 4.58%. Indaptus (INDP) shares surged 16.88% without specific news.

Tenon Medical (TNON) repaid $5.16M in notes, strengthening its balance sheet. AEON Biopharma (AEON) reported positive study results for ABP-450. Silexion (SLXN) announced September conference participations. Orchestra BioMed (OBIO) and Indaptus (INDP) also shared updates, with shares rising.

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 8, 2026, Indaptus Therapeutics, Inc. (the “ Company ”) entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) with the purchasers party thereto (collectively, the “ Purchasers ”), pursuant to which

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 2, 2026, Tim Ruan notified the Board of Directors (the “ Board ”) of Indaptus Therapeutics, Inc. (the “ Compa

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On August 28, 2026, Indaptus Therapeutics, Inc. (the “ Company ”) entered into an Amended and Restated At the Market Offering Agreement (the “ Sales Agreement ”) with H.C. Wainwright & Co., LLC (“ Wainwright ”), which amends

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK (August 13, 2026) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to immunotherapy research, today

Indaptus Therapeutics (Nasdaq: INDP) reported Q2 2026 results and a corporate update. It raised about $12.0 million via a June 17 private placement at $0.60 per share. The company discontinued further Decoy20 enrollment and has no active clinical programs. Q2 R&D fell to ~$0.4M and net loss to ~$1.8M. Cash and short-term investments were ~$11.6M at June 30.